BioInformant

Your Global Leader in Stem Cell Market Research

Home » Cord Blood » Page 2

Cesca Partners with Healthbank Biotech (Stem Cell Bank) to Provide Immune Cell Banking

By

ImmuneCyte to Begin Operations in Fourth Quarter of 2019

RANCHO CORDOVA, Calif., Oct. 22, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture agreement with HealthBanks Biotech (USA) Inc., one of the world’s leading stem cell bank networks, to commercialize its proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). The joint venture will be named ImmuneCyte Life Sciences Inc. (“ImmuneCyte”) and is expected to officially launch during the fourth quarter of 2019. [Read more…]

CBR to Acquire Natera’s Evercord™ Cord Blood Business for an Undisclosed Sum

By

Cord Blood Registry (CBR), a California Cryobank Life Sciences company, has announced it will acquire Natera’s Evercord™ cord blood business for an undisclosed sum. CBR is the largest newborn stem cell collection and storage company within the United States with more than 875,000 stem cell samples in storage. Natera is a publicly listed company (NASDAQ: NTRA) that specializes in genetic testing services. [Read more…]

Cord Blood Industry Consolidation Escalates as 2020 Approaches

By

The global cord blood industry experienced strong growth from the early 1990’s through the mid 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.

Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation.

Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, and Latin America.

With CBR’s recent acquisition of Natera’s Evercord™ Cord Blood Business on September 13, 2019, the trend of cord blood industry consolidation continues. [Read more…]

Where Do Stem Cells Come From? | Basics Of Stem Cell Therapy

By

Where do stem cells come from? Learn the basics of master cells to better understand their therapeutic potential.

In this article:

  1. An Introduction to Human Stem Cells
  2. Types of Stem Cells
  3. Where Do Stem Cells Come From?
  4. The Donation Process
  5. What Can Stem Cells Treat?
  6. Stem Cells for Testing New Drugs
  7. The Benefits of Stem Cell Transplant
  8. The Survival Rate of Stem Cell Therapy

[Read more…]

Will I See You at Phacilitate Leaders World 2020 (Psst, Get 10% Off)

By

Advanced therapy companies have been rapidly populating over the past few years, making it a high-value, fast-growth industry. Key drivers include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for advanced therapies to revolutionize healthcare.

Stem Cell Industry Growth

Stem cell treatments are one of several segments that compose the advanced therapies industry, which includes but is not limited to cell therapy, gene therapy, and tissue engineering applications.

Stem cells have gained tremendous momentum over the last decade. As of November 2019, stem cell scientific publications have reached over 364,930 worldwide, with 25,000+ now being published per year.

Number of Stem Cell Scientific Publications Worldwide

For stem cell clinical trials, 7,400+ have been registered on ClinicalTrials.gov. Because this registry includes approximately 3/4ths of clinical trials worldwide, the total number of stem cell clinical trials worldwide is estimated to be approaching 10,000.

[Read more…]

BioInformant's World-Class Clients